SRPT logo

Sarepta Therapeutics, Inc.

SRPT
Healthcare|Biotechnology|US
$17.82
+0.25 (+1.42%)
Tangible Book / Share
$14.15
Graham Number
$6.73
Cash / Share
$8.30

Financials

Financial Snapshot

Market Cap
$1.88B
Enterprise Value
$2.46B
Revenue (TTM)
$1.96B
Net Income (TTM)
$14.8M
Cash & Investments
$878.8M
Net Cash
-$174.3M
Free Cash Flow (TTM)
-$31.6M
Operating CF (TTM)
-$17.1M
Debt/Equity
0.69

Cash Runway & Burn Rate

Cash on Hand
$878.8M
Quarterly Burn
$4.3M
Monthly Burn
$1.4M
Est. Runway
~205.3 quarters
MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$317.8M$1.08B$1.17B$1.12B$1.94B$2.12B$1.99B$1.68B$1.35B$939.6M$878.8M
Operating Cash Flow
-$245.8M-$232.0M-$388.7M-$456.5M$107.5M-$443.2M-$325.3M-$501.0M-$205.8M-$205.5M-$17.1M
Free Cash Flow
-$252.7M-$253.2M-$453.0M-$516.1M$25.3M-$481.7M-$357.6M-$588.3M-$352.7M-$307.5M-$31.6M
Capital Expenditure
-$6.9M-$21.2M-$64.3M-$59.6M-$82.2M-$38.5M-$32.3M-$87.3M-$147.0M-$102.0M-$14.5M
Financing Cash Flow
$378.1M$888.1M$530.1M$642.6M$682.3M$561.6M$232.5M$125.0M$124.8M-$168.3M-$38.7M

R&D Spending

R&D (TTM)
$653.1M
R&D Intensity
33.4%
R&D Growth vs Prior
-57.1%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$5.4M$154.6M$301.0M$380.8M$540.1M$701.9M$933.0M$1.24B$1.90B$2.20B$1.96B
R&D Expense
$188.3M$166.7M$401.8M$560.9M$722.3M$771.2M$877.1M$877.4M$804.5M$1.52B$653.1M
R&D % of Revenue
3473.0%107.8%133.5%147.3%133.7%109.9%94.0%70.6%42.3%69.2%33.4%
SG&A
$83.7M$122.7M$207.8M$284.8M$317.9M$282.7M$451.4M$481.9M$557.9M$478.9M$463.5M

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$5.4M$154.6M$301.0M$380.8M$540.1M$701.9M$933.0M$1.24B$1.90B$2.20B$1.96B
Cost of Revenue
$130.0K$7.4M$34.2M$56.6M$63.4M$97.0M$140.0M$150.3M$319.1M$881.5M$856.0M
Gross Profit
$5.3M$147.2M$266.8M$324.2M$476.7M$604.8M$793.0M$1.09B$1.58B$1.32B$1.10B
R&D
$188.3M$166.7M$401.8M$560.9M$722.3M$771.2M$877.1M$877.4M$804.5M$1.52B$653.1M
SG&A
$83.7M$122.7M$207.8M$284.8M$317.9M$282.7M$451.4M$481.9M$557.9M$478.9M$463.5M
Operating Income
-$266.7M-$171.6M-$343.6M-$705.6M-$564.2M-$459.7M-$536.2M-$267.8M$218.1M-$657.8M-$48.9M
Interest Expense
$1.9M$5.8M$33.7M$30.7M$59.9M$63.5M$53.2M$22.0M$18.4M$9.7M$72.4M
Pretax Income
-$267.3M-$48.6M-$362.6M-$713.9M-$553.1M-$418.9M-$690.0M-$520.1M$260.8M-$702.2M$37.4M
Net Income
-$267.3M-$50.7M-$361.9M-$715.1M-$554.1M-$418.8M-$703.5M-$536.0M$235.2M-$713.4M$14.8M
EPS (Diluted)
-5.49-0.86-5.46-9.71-7.11-5.15-8.03-5.802.34-7.13-1.37
EBITDA
-$261.1M-$34.8M-$316.7M-$658.7M-$453.4M-$317.4M-$594.9M-$453.7M$316.9M-$648.0M$155.2M
Shares Out. (M)
48.7058.8266.2573.6177.9681.2687.5692.40107.88104.79105.93

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$122.4M$599.7M$370.8M$835.1M$1.50B$2.12B$966.8M$428.4M$1.10B$801.3M$472.8M
Short-Term Investments
$195.4M$479.4M$803.1M$289.7M$435.9M$0.00$1.02B$1.25B$251.8M$138.4M$406.0M
Total Current Assets
$373.5M$1.23B$1.43B$1.47B$2.49B$2.60B$2.56B$2.58B$3.07B$2.54B$2.27B
Total Assets
$424.1M$1.31B$1.64B$1.82B$2.98B$3.15B$3.13B$3.26B$3.96B$3.35B$3.17B
Total Current Liabilities
$75.4M$88.3M$173.7M$264.8M$416.0M$452.7M$619.6M$653.7M$731.7M$1.10B$656.4M
Long-Term Debt
$6.0M$424.9M$420.6M$681.9M$992.5M$1.10B$1.54B$1.13B$1.14B$829.0M$699.4M
Total Liabilities
$87.4M$518.7M$609.8M$1.00B$2.22B$2.22B$2.74B$2.41B$2.44B$2.21B$1.64B
Stockholders' Equity
$336.7M$789.2M$1.03B$818.2M$761.8M$928.0M$384.9M$859.3M$1.53B$1.14B$1.53B
Retained Earnings
-$1.17B-$1.22B-$1.58B-$2.29B-$2.85B-$3.21B-$3.91B-$4.45B-$4.21B-$4.88B-$4.58B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
-$245.8M-$232.0M-$388.7M-$456.5M$107.5M-$443.2M-$325.3M-$501.0M-$205.8M-$205.5M-$17.1M
Capital Expenditure
-$6.9M-$21.2M-$64.3M-$59.6M-$82.2M-$38.5M-$32.3M-$87.3M-$147.0M-$102.0M-$14.5M
Free Cash Flow
-$252.7M-$253.2M-$453.0M-$516.1M$25.3M-$481.7M-$357.6M-$588.3M-$352.7M-$307.5M-$31.6M
Investing Cash Flow
-$90.2M-$178.8M-$370.5M$286.7M-$121.7M$495.4M-$1.05B-$165.8M$755.6M$69.6M-$424.3M
Financing Cash Flow
$378.1M$888.1M$530.1M$642.6M$682.3M$561.6M$232.5M$125.0M$124.8M-$168.3M-$38.7M
Issuance of Stock
$364.8M$354.0M$513.4M$365.4M$312.1M$548.5M$0.00$0.00$0.00$36.3M$680.0K
Repurchase of Stock
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00-$25.0M$0.00
Net Debt Issuance
-$7.6M$585.0M-$33.5M$245.6M$291.1M$0.00$304.2M$0.00-$68.0K-$162.6M-$35.1M
Stock Based Comp.
$30.0M$30.5M$50.1M$78.6M$108.1M$113.9M$233.0M$182.5M$184.3M$123.4M$140.0M
Net Change in Cash
$42.1M$477.3M-$229.0M$472.8M$668.1M$613.8M-$1.14B-$541.8M$674.6M-$304.2M-$480.1M

Dilution Tracker

Shares outstanding grew 34.4% over 5 years — significant dilution
Shares Outstanding
106M
5-Year Share Growth
+34.4%
Stock Issuance (TTM)
$680.0K
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
48.7058.8266.2573.6177.9681.2687.5692.40107.88104.79105.93
Change vs Prior %
—20.8%12.6%11.1%5.9%4.2%7.7%5.5%16.8%-2.9%1.1%
Stock Issuance
$364.8M$354.0M$513.4M$365.4M$312.1M$548.5M$0.00$0.00$0.00$36.3M$680.0K
Stock Repurchase
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00-$25.0M$0.00
Stock Based Comp.
$30.0M$30.5M$50.1M$78.6M$108.1M$113.9M$233.0M$182.5M$184.3M$123.4M$140.0M

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
97.6%95.2%88.6%85.1%88.3%86.2%85.0%87.9%83.2%59.9%56.2%
Operating Margin %
-4920.3%-111.0%-114.1%-185.3%-104.5%-65.5%-57.5%-21.5%11.5%-29.9%-2.5%
Net Margin %
-4930.2%-32.8%-120.2%-187.8%-102.6%-59.7%-75.4%-43.1%12.4%-32.5%0.8%
EBITDA Margin %
-4816.8%-22.5%-105.2%-173.0%-83.9%-45.2%-63.8%-36.5%16.7%-29.5%7.9%
FCF Margin %
-4661.2%-163.8%-150.5%-135.5%4.7%-68.6%-38.3%-47.3%-18.5%-14.0%-1.6%
ROE %
-79.4%-6.4%-35.1%-87.4%-72.7%-45.1%-182.7%-62.4%15.4%-62.5%1.0%
ROA %
-63.0%-3.9%-22.0%-39.2%-18.6%-13.3%-22.5%-16.4%5.9%-21.3%0.5%
ROIC %
-74.3%-14.0%-23.4%-45.1%-21.8%-17.0%-21.2%-9.8%6.1%-29.0%-0.7%
R&D / Revenue %
3473.0%107.8%133.5%147.3%133.7%109.9%94.0%70.6%42.3%69.2%33.4%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
332.6%2751.6%94.7%26.5%41.8%30.0%32.9%33.3%53.0%15.6%
Gross Profit
103.7%2682.7%81.2%21.5%47.0%26.9%31.1%37.8%44.8%-16.8%
Operating Income
-21.1%35.7%-100.2%-105.3%20.0%18.5%-16.6%50.1%181.4%-401.6%
Net Income
-21.5%81.0%-614.0%-97.6%22.5%24.4%-68.0%23.8%143.9%-403.3%
EPS (Diluted)
-5.6%84.3%-534.9%-77.8%26.8%27.6%-55.9%27.8%140.3%-404.7%
Operating Cash Flow
-64.5%5.6%-67.5%-17.4%123.5%-512.4%26.6%-54.0%58.9%0.1%
Free Cash Flow
-63.8%-0.2%-78.9%-13.9%104.9%-2006.5%25.8%-64.5%40.0%12.8%
R&D Expense
28.6%-11.5%141.0%39.6%28.8%6.8%13.7%0.0%-8.3%89.2%
SG&A Expense
11.6%46.5%69.3%37.1%11.6%-11.1%59.7%6.7%15.8%-14.1%
Total Assets
54.9%208.4%25.5%11.0%63.7%5.5%-0.6%4.4%21.4%-15.5%
Book Value / Share
53.7%94.0%16.1%-28.7%-12.1%16.9%-61.5%111.5%72.8%-32.3%
Debt
-31.0%2569.0%-2.4%75.4%48.3%5.5%40.2%-13.6%-3.8%-22.6%
Diluted Shares
15.2%20.8%12.6%11.1%5.9%4.2%7.7%5.5%16.8%-2.9%

Valuation

P/E (TTM)198.00
P/S0.96
10Y Low / Med / High1.03 / 21.17 / 246.33
P/B1.23
10Y Low / Med / High1.98 / 7.89 / 29.47
EV/EBITDA15.87
EV/Revenue1.26
10Y Low / Med / High1.13 / 20.08 / 226.73
P/FCFAt Loss

Intrinsic Value Models (per share)

Tangible Book / Share
$14.15
Net Current Assets / Share
$6.02
Graham Number
$6.73
Cash / Share
$8.30
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
-5.00-64.70-19.99-13.29-23.98-17.49-16.14-16.6349.23-3.02198.00
P/S Ratio
246.3321.1724.0224.9424.6110.4312.167.176.081.030.96
P/B Ratio
3.974.157.0011.6117.457.8929.4710.377.571.981.23
EV/EBITDA
-4.71-89.31-22.99-14.27-28.41-20.02-20.17-21.7737.24-3.8515.87
EV/Revenue
226.7320.0824.1824.6923.859.0512.867.956.201.131.26

Analyst Estimates & Quality

Altman Z-Score
0.02
Distress
Piotroski F-Score
4
Moderate

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$1.84B$1.41B$1.35B
Net Income$335.7M$40.6M-$38.6M
EPS$3.08$0.34$-0.03
# Analysts (EPS)111111

Revenue Segments

By Geography

Segment2022202320242025
Non-US$96.7M——$165.2M
UNITED STATES$747.1M$797.9M$820.8M$898.7M
Rest of World—$146.6M$150.2M—